IP Library Granted Patent US 7,648,703
Granted Patent B2
US 7,648,703 · App. 11/034,655 · Granted Jan 19, 2010

Combination of anti-EP-CAM antibody with a chemotherapeutic agent

Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,648,703
App. No.
11/034,655
Granted
Jan 19, 2010
Kind
B2
Abstract

A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G 2 /M.

Claims (4)

1. A combination comprising: an anti-Ep-CAM antibody with a chemotherapeutic agent wherein the chemotherapeutic agent is capable of arresting cell cycle production in S and/or G2/M in Ep-CAM expressing tumor cells and increasing the density of the Ep-Cam antigen population of the Ep-CAM expressing tumor cells, selected from the group consisting of: UFT, Capecitabine, CPT-II, Oxaliplatin, Paclitaxel, Docetaxel, Cyclophosphamide, Methotrexate, Doxorubicin, Navelbine (iv and oral), Epirubicin, Mitoxantrone, Raloxifen, Cisplatin, Carboplatinum, Gemcitabine, Etoposide and Topotecan.

2. The combination according to claim 1 wherein the Ep-CAM antibody is Panorex.

3. A combination comprising an anti-Ep-CAM antibody with a chemotherapeutic agent wherein the chemotherapeutic agent is capable of arresting of cell cycle production in S and/or G2/M in Ep-CAM expressing tumor cells and increasing the density of the Ep-Cam antigen population of the Ep-CAM expressing tumor cells, and wherein the chemotherapeutic agent is Docetaxel.

4. A combination comprising an anti-Ep-CAM antibody with a chemotherapeutic wherein the chemotherapeutic agent is agent capable of arresting of cell cycle production in S and/or G2/M in Ep-CAM expressing tumor cells, and increasing the density of the Ep-Cam antigen population of the Ep-CAM expressing tumor cells, and wherein the chemotherapeutic agent is Paclitaxel.

Assignments (2)
CHANGE OF NAME Recorded Dec 2, 2009
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023590/0304 →
MERGER Recorded Dec 1, 2009
From: GLAXO WELLCOME INC.
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 023584/0253 →
Continuity (2)
Continuation 1003135500
Related Publication 20050163785A1 · Jul 28, 2005